Philips Gets FDA Approval for Ultrasonic Products in Covid-19 Related Cases
May 13 2020 - 9:42AM
Dow Jones News
By Sabela Ojea
Koninklijke Philips N.V. said Wednesday that it has received
clearance from the U.S. Food and Drug Administration to sell a
range of ultrasonic solutions aimed at the control of Covid-19
related lung and cardiac complications.
The Dutch technology company said ultrasound solutions have
proved their utility in imaging peripheral lung tissue affected by
pneumonia, one of the potential side effects of Covid-19.
"With this regulatory clearance we can offer clear guidance to
ensure safe and effective use of ultrasound... At the same time, we
are investing significantly to ramp up production globally,
including at our ultrasound manufacturing plants in the U.S.," said
Bich Le, senior vice president and general manager of Ultrasound at
Philips.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 13, 2020 09:27 ET (13:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024